Lisinopril
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Lisinopril
- Generic name
- LISINOPRIL
- Manufacturer
- Chartwell RX, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 8824e5e5-ed35-4a95-bfd6-98a2e7c4bbce
- SPL ID
- 462a5023-e5a0-692a-e063-6294a90a7236
- Version
- 3
- Effective date
- 2025-12-17
- Source export date
- 2026-09-28
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/c7ca0b7091cdaeab3f27713a6eef00adcf8fe722383633ddce61531b4c840544/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:27:15
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 208920 | derived:openfda.application_number |
| application applno | ANDA | 212041 | derived:openfda.application_number |
| application number | ANDA208920 | openfda.application_number | |
| application number | ANDA212041 | openfda.application_number | |
| brand name | Lisinopril | openfda.brand_name | |
| generic name | LISINOPRIL | openfda.generic_name | |
| manufacturer name | Chartwell RX, LLC | openfda.manufacturer_name | |
| ndc | package | 62135-641-90 | openfda.package_ndc |
| ndc | package | 62135-643-31 | openfda.package_ndc |
| ndc | package | 62135-644-90 | openfda.package_ndc |
| ndc | package | 62135-641-31 | openfda.package_ndc |
| ndc | package | 62135-642-31 | openfda.package_ndc |
| ndc | package | 62135-645-31 | openfda.package_ndc |
| ndc | package | 62135-645-90 | openfda.package_ndc |
| ndc | package | 62135-644-31 | openfda.package_ndc |
| ndc | package | 62135-643-90 | openfda.package_ndc |
| ndc | package | 62135-640-90 | openfda.package_ndc |
| ndc | package | 62135-640-31 | openfda.package_ndc |
| ndc | package | 62135-642-90 | openfda.package_ndc |
| ndc | product | 62135-641 | openfda.product_ndc |
| ndc | product | 62135-642 | openfda.product_ndc |
| ndc | product | 62135-645 | openfda.product_ndc |
| ndc | product | 62135-640 | openfda.product_ndc |
| ndc | product | 62135-643 | openfda.product_ndc |
| ndc | product | 62135-644 | openfda.product_ndc |
| ndc11 | package | 62135064131 | derived:openfda.package_ndc |
| ndc11 | package | 62135064590 | derived:openfda.package_ndc |
| ndc11 | package | 62135064031 | derived:openfda.package_ndc |
| ndc11 | package | 62135064190 | derived:openfda.package_ndc |
| ndc11 | package | 62135064290 | derived:openfda.package_ndc |
| ndc11 | package | 62135064490 | derived:openfda.package_ndc |
| ndc11 | package | 62135064531 | derived:openfda.package_ndc |
| ndc11 | package | 62135064390 | derived:openfda.package_ndc |
| ndc11 | package | 62135064431 | derived:openfda.package_ndc |
| ndc11 | package | 62135064331 | derived:openfda.package_ndc |
| ndc11 | package | 62135064090 | derived:openfda.package_ndc |
| ndc11 | package | 62135064231 | derived:openfda.package_ndc |
| rxcui | 314077 | openfda.rxcui | |
| rxcui | 197884 | openfda.rxcui | |
| rxcui | 205326 | openfda.rxcui |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue lisinopril tablets as soon as possible [see Warnings and Precautions (5.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue lisinopril tablets as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS Angioedema: Discontinue Lisinopril Tablets, provide appropriate therapy and monitor until resolved ( 5.2 ) Renal impairment: Monitor renal function periodically ( 5.3 ) Hypotension: Patients with other heart or renal diseases have increased risk, monitor blood pressure after initiation ( 5.4 ) Hyperkalemia: Monitor serum potassium periodically ( 5.5 ) Cholestatic jaundice and hepatic failure: Monitor for jaundice or signs of liver failure ( 5.6 )
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Common adverse reactions (events 2% greater than placebo) by use: Hypertension: headache, dizziness and cough ( 6.1 ) Heart Failure: hypotension and chest pain ( 6.1 ) Acute Myocardial Infarction: hypotension ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Chartwell RX, LLC. at 1-845-232-1683 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.